Advocacy intelligence hub — real-time data for patient organizations
Grand Shuyang Life Sciences (Chengdu) Co., Ltd. — PHASE3
University of Minnesota — PHASE2
Fundación Española de Hematología y Hemoterapía
University of Cologne
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Doptelet
Sobi, Inc.
Patient Assistance Programs1
Adzynma
TAKEDA PHARMACEUTICALS AMERICA, INC.
Doptelet
(avatrombopag)Orphan drugSobi, Inc.
12.1 Mechanism of Action Avatrombopag is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation...
Adzynma
(APADAMTASE ALFA)Orphan drugTAKEDA PHARMACEUTICALS AMERICA, INC.
12.1 Mechanism of Action ADZYNMA is a recombinant form of the endogenous ADAMTS13. ADAMTS13 is a plasma zinc metalloprotease that regulates the activi...
Cablivi
(CAPLACIZUMAB)Orphan drugstandardGenzyme Corporation
12.1 Mechanism of Action Caplacizumab-yhdp targets the A1-domain of vWF, and inhibits the interaction between vWF and platelets, thereby reducing both...
Browse all Immune-mediated thrombotic thrombocytopenic purpura news →
Xiaohui Zhang, MD, MD
Peking University People's Hospital
📍 Beijing, FL
Ilaria Mancini, PhD
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Marshall Mazepa, MD, M.D
University of Minnesota
📍 MINNEAPOLIS, MN
Xiao-Hui Zhang, MD
Peking University Institute of Hematology, Peking University People's Hospital
Jehane Fadlallah
Centre de Référence des Microangiopathies Thrombotiques et Service d'hématologie
Karen Vanhoorelbeke
Laboratory for Thrombosis Research
View all Immune-mediated thrombotic thrombocytopenic purpura specialists →